Browsing: Metabolic Syndrome & Insulin Resistance

Metabolic syndrome, insulin resistance, prediabetes physiology, and cardiometabolic risk.

All

The DREAM trial demonstrated that rosiglitazone reduces incident diabetes or death by 60% and achieves normoglycaemia in 50% of high-risk adults with impaired glucose tolerance, the largest pharmacological diabetes prevention effect documented in a large RCT, but the drug’s subsequent cardiovascular safety concerns and market withdrawal have prevented translation of these findings into clinical practice.